This article is more than 5 years old. Information may no longer be current.
Study showed effective treatment of chronic osteomyelitis with single-stage procedure
Click Here to Manage Email Alerts
Recently published results showed patients who had chronic osteomyelitis were effectively treated through a single-stage protocol facilitated by an absorbable local antibiotic.
Researchers treated 100 patients with chronic osteomyelitis with a single-stage protocol that included debridement, multiple sampling, culture-specific systemic antibiotics, stabilization, dead space filling with a biocomposite (Cerament G, Bonesupport) and primary skin closure.
At a mean follow-up of 19.5 months, results showed 96 patients had their infection eradicated with a single procedure. While researchers found recurrence of infection in four patients, after revision surgery, all patients remained infection-free at 13 months, 16 months, 17 months and 20 months. According to results, adverse events included three fractures, six wound leaks and three unrelated deaths. Researchers noted Cierny-Mader host class, microbial culture, wound leakage or presence of nonunion did not influence outcome.
“The results that we have achieved with the single-stage surgical procedure using Cerament G for the dead space management of patients with chronic osteomyelitis are a significant improvement on past experience,” Martin A. McNally, MD, FRCSEd, FRCS (Orth), consultant bone infection and limb reconstruction surgeon at Oxford University Hospitals, said in a company press release. “These results reflect Cerament G’s unique local antibiotic delivery profile and its attractive bone remodeling capabilities. We are increasingly using Cerament G in the treatment of patients with chronic osteomyelitis and infected fractures. It allows a more patient-friendly treatment, preventing repeated operations and recurrent infections. We expect it to become the mainstay of our dead space management, given the major clinical and health economic benefits that it supports.” – by Casey Tingle
Reference:
Disclosures: Ferguson reports he was partly supported by an unrestricted research grant from Bonesupport AB, Lund, Sweden. The author or one or more of the authors have received or will receive benefits for personal or professional use from a commercial party related directly or indirectly to the subject of this article.
Click Here to Manage Email Alerts